Gain Therapeutics Q2 EPS $(0.11) Beats $(0.14) Estimate
Gain Therapeutics (NASDAQ:GANX) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.14) by 21.43 percent. This is a 42.11 percent increase over losses of $(0.19) per share
Gain Therapeutics lost less money per share than people thought it would, and it's also losing less money than it did a year ago. When a company loses less money over time, that shows it's moving in a better direction, even though it's still not making a profit yet.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.